Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Taiko Pharmaceutical Co stock price, quote, forecast and news

4574.T
JP3442200006

Price

452.00
Today +/-
+0
Today %
+0 %
P

Taiko Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Taiko Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Taiko Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Taiko Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Taiko Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Taiko Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Taiko Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Taiko Pharmaceutical Co’s growth potential.

Taiko Pharmaceutical Co Revenue, EBIT and net profit per share

DateTaiko Pharmaceutical Co RevenueTaiko Pharmaceutical Co EBITTaiko Pharmaceutical Co Net Income
20236.12 B undefined-1.01 B undefined-3.61 B undefined
20225.04 B undefined-3.08 B undefined-4.9 B undefined
202111.3 B undefined-4.95 B undefined-9.59 B undefined
202017.58 B undefined5.65 B undefined3.85 B undefined
201914.97 B undefined3.82 B undefined2.45 B undefined
201810.42 B undefined2.03 B undefined1.42 B undefined
20179.46 B undefined1.86 B undefined1.09 B undefined
20168.29 B undefined1.55 B undefined1.05 B undefined
20158.33 B undefined1.35 B undefined840.11 M undefined
20148.98 B undefined2.56 B undefined1.77 B undefined
20139.95 B undefined2.59 B undefined1.75 B undefined
20127.44 B undefined1.12 B undefined1.04 B undefined
20116.68 B undefined515 M undefined482 M undefined
20104.62 B undefined-1.24 B undefined-2.23 B undefined
20098.82 B undefined2.49 B undefined1.65 B undefined
20086.09 B undefined894 M undefined471 M undefined
20075.54 B undefined656 M undefined360 M undefined
20064.94 B undefined520 M undefined379 M undefined
20055.07 B undefined367 M undefined207 M undefined
20041.61 B undefined-119 M undefined92 M undefined

Taiko Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
4.594.711.615.074.945.546.098.824.626.687.449.958.988.338.299.4610.4214.9717.5811.35.046.12
-2.77-65.84214.66-2.5912.289.9844.67-47.6144.7111.3733.62-9.74-7.25-0.4014.0510.1443.6617.49-35.74-55.3921.43
69.5469.6867.3370.7975.0871.0373.0272.3665.7167.0667.6573.0373.7869.3067.2869.4969.1370.8870.0629.4421.4142.11
3.193.281.083.593.713.944.456.383.044.485.047.266.625.775.586.577.210.6112.323.331.082.58
0.120.23-0.120.370.520.660.892.49-1.240.521.122.592.561.351.551.862.033.825.65-4.95-3.08-1.01
2.704.94-7.397.2410.5411.8414.6728.23-26.897.7015.0626.0528.5016.1818.6319.6319.4825.5532.13-43.78-61.09-16.42
0.06-0.110.090.210.380.360.471.65-2.230.481.041.751.770.841.051.091.422.453.85-9.59-4.9-3.61
--270.97-186.79125.0083.09-5.0130.83249.26-235.44-121.63115.3568.301.32-52.5424.884.2929.3473.3656.99-349.13-48.98-26.23
12121212131313131313131339.539.4941.5242.6242.9442.7943.1943.5143.647.36
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Taiko Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Taiko Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Taiko Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Taiko Pharmaceutical Co's financial health and stability.

Assets

Taiko Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Taiko Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Taiko Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Taiko Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20062007200820092010201120122013201420152016201720182019202020212022
0.750.60.692.59-20.411.12.552.761.191.491.551.993.55.37-8.89-4.87
157164176212241258250258280350444453460495472941737
00000000000000000
-0.42-0.740.04-1-0.68-0.53-0.210.58-1.62-1.110.65-2.22-0.54-0.85-7.083.382.17
-0.10.230.230.090.750.39-0.060.19-0.73-0.060.120.16-0.160.34-0.292.97-0.03
800000000200000610
0.30.490.190.330.850.010.010.131.080.650.360.570.570.721.421.030.02
0.380.261.141.9-1.690.531.083.590.690.382.7-0.061.753.49-1.52-1.6-1.99
-83-162-563-225-197-180-211-303-2,881-3,718-111-128-505-220-2,225-1,600-84
1418-564-111828-11713-620-2,754-2,635-72-113-746-448-2,759-1,622190
0.230.1700.111.030.060.23-0.320.131.080.040.01-0.24-0.23-0.53-0.020.27
00000000000000000
-0.05-0.3-0-0.01-0.02-0.02-0.02-0.02-0.01-0.01-0.01-0.02-0.02-0.03-0.034.64-0.97
00.04000.080.04-0.240.21-0.50.171.460.190.18-0.050.220.10
-0.06-0.27-0.01-0.03-0.06-0.02-0.450.02-0.83-0.141.25-0.07-0.34-0.58-0.653.96-1
0000018022026031000-1-30
-10-10-10-21-126-62-194-190-324-319-195-282-498-499-845-7820
0.49-0.050.511.76-0.980.380.683.09-2.78-2.443.81-0.260.652.45-4.950.82-2.72
296.399.55741,671.1-1,888.1353.4866.73,285.6-2,191.12-3,340.642,586.02-188.231,242.573,273.03-3,742.2-3,196-2,077
00000000000000000

Taiko Pharmaceutical Co stock margins

The Taiko Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Taiko Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Taiko Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Taiko Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Taiko Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Taiko Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Taiko Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Taiko Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Taiko Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Taiko Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Taiko Pharmaceutical Co Margin History

Taiko Pharmaceutical Co Gross marginTaiko Pharmaceutical Co Profit marginTaiko Pharmaceutical Co EBIT marginTaiko Pharmaceutical Co Profit margin
202342.11 %-16.42 %-59 %
202221.41 %-61.09 %-97.12 %
202129.44 %-43.78 %-84.91 %
202070.07 %32.14 %21.91 %
201970.88 %25.55 %16.39 %
201869.13 %19.48 %13.59 %
201769.49 %19.63 %11.58 %
201667.28 %18.63 %12.65 %
201569.3 %16.18 %10.09 %
201473.77 %28.5 %19.72 %
201373.03 %26.05 %17.56 %
201267.65 %15.06 %13.94 %
201167.06 %7.7 %7.21 %
201065.71 %-26.89 %-48.24 %
200972.36 %28.23 %18.66 %
200873.02 %14.67 %7.73 %
200771.03 %11.84 %6.5 %
200675.08 %10.54 %7.68 %
200570.79 %7.24 %4.09 %
200467.33 %-7.39 %5.71 %

Taiko Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Taiko Pharmaceutical Co earnings per share therefore indicates how much revenue Taiko Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Taiko Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Taiko Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Taiko Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Taiko Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Taiko Pharmaceutical Co Revenue, EBIT and net profit per share

DateTaiko Pharmaceutical Co Sales per ShareTaiko Pharmaceutical Co EBIT per shareTaiko Pharmaceutical Co Earnings per Share
2023129.22 undefined-21.22 undefined-76.25 undefined
2022115.59 undefined-70.62 undefined-112.27 undefined
2021259.69 undefined-113.7 undefined-220.51 undefined
2020407.11 undefined130.84 undefined89.18 undefined
2019349.76 undefined89.38 undefined57.34 undefined
2018242.62 undefined47.27 undefined32.96 undefined
2017221.92 undefined43.57 undefined25.69 undefined
2016199.76 undefined37.22 undefined25.27 undefined
2015210.89 undefined34.13 undefined21.28 undefined
2014227.34 undefined64.8 undefined44.83 undefined
2013765.15 undefined199.31 undefined134.38 undefined
2012572.62 undefined86.23 undefined79.85 undefined
2011514.15 undefined39.62 undefined37.08 undefined
2010355.31 undefined-95.54 undefined-171.38 undefined
2009678.15 undefined191.46 undefined126.54 undefined
2008468.77 undefined68.77 undefined36.23 undefined
2007426.23 undefined50.46 undefined27.69 undefined
2006379.62 undefined40 undefined29.15 undefined
2005422.17 undefined30.58 undefined17.25 undefined
2004134.17 undefined-9.92 undefined7.67 undefined

Taiko Pharmaceutical Co business model

Taiko Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Taiko Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Taiko Pharmaceutical Co shares outstanding

The number of shares was Taiko Pharmaceutical Co in 2023 — This indicates how many shares 47.36 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Taiko Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Taiko Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Taiko Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Taiko Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Taiko Pharmaceutical Co Stock splits

In Taiko Pharmaceutical Co's history, there have been no stock splits.

Taiko Pharmaceutical Co dividend history and estimates

In 2023, Taiko Pharmaceutical Co paid a dividend amounting to 0 JPY. Dividend means that Taiko Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Taiko Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Taiko Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Taiko Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Taiko Pharmaceutical Co Dividend History

DateTaiko Pharmaceutical Co Dividend
202023.67 undefined
20198.33 undefined
20188.33 undefined
20175 undefined
20165 undefined
20155 undefined
20145 undefined
20133.33 undefined
20123.33 undefined
20111.67 undefined
20101.67 undefined
20090.28 undefined

Taiko Pharmaceutical Co dividend payout ratio

In 2023, Taiko Pharmaceutical Co had a payout ratio of 23.24%. The payout ratio indicates the percentage of the company's profits that Taiko Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Taiko Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Taiko Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Taiko Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Taiko Pharmaceutical Co Payout Ratio History

DateTaiko Pharmaceutical Co Payout ratio
202323.24 %
202221.06 %
202122.12 %
202026.54 %
201914.53 %
201825.28 %
201719.46 %
201619.78 %
201523.5 %
201411.15 %
20132.48 %
20124.17 %
20114.5 %
2010-0.97 %
20090.22 %
200822.12 %
200722.12 %
200622.12 %
200522.12 %
200422.12 %
Unfortunately, there are currently no price targets and forecasts available for Taiko Pharmaceutical Co.

Taiko Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
7.78 % Royal Bank of Canada3,903,065438,75012/31/2023
6.57 % Shibata (Takashi)3,294,439012/31/2023
6.53 % Shibata (Hitoshi)3,274,816012/31/2023
6.35 % Kingworld Medicines Health Management Limited3,185,9003,185,9008/15/2023
4.91 % UBS AG Hong Kong2,462,700012/31/2023
3.78 % Shibata (Akihiro)1,897,047012/31/2023
2.61 % Earth Corp1,311,400012/31/2023
2.61 % Kowa Co., Ltd.1,308,000012/31/2023
2.49 % Nomura Asset Management Co., Ltd.1,248,500146,80010/13/2023
2.42 % Shibata (Wataru)1,213,347012/31/2023
1
2
3
4

Taiko Pharmaceutical Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Totech Stock
Totech
SupplierCustomer0,600,180,370,620,82-0,34
Earth Stock
Earth
SupplierCustomer0,520,720,720,910,810,72
PALTAC Stock
PALTAC
SupplierCustomer0,500,12-0,240,340,840,55
Alfresa Holdings Stock
Alfresa Holdings
SupplierCustomer0,310,40-0,20-0,68-0,85
DENSO Stock
DENSO
SupplierCustomer0,120,140,750,69-0,23-0,92
Ohki Health Care Holdings Stock
Ohki Health Care Holdings
SupplierCustomer-0,09-0,150,460,710,940,77
RBC Stock
RBC
SupplierCustomer-0,69-0,380,21-0,40-0,79-0,95
1

Most common questions regarding Taiko Pharmaceutical Co

What is the P/E ratio of Taiko Pharmaceutical Co 2024?

The P/E ratio cannot be calculated for Taiko Pharmaceutical Co at the moment.

What is the P/S ratio of Taiko Pharmaceutical Co 2024?

The P/S cannot be calculated for Taiko Pharmaceutical Co currently.

What is the AlleAktien quality score of Taiko Pharmaceutical Co?

The AlleAktien quality score for Taiko Pharmaceutical Co is 1/10.

What is the revenue of Taiko Pharmaceutical Co 2024?

The revenue cannot currently be calculated for Taiko Pharmaceutical Co.

How high is the profit of Taiko Pharmaceutical Co 2024?

The profit cannot currently be calculated for Taiko Pharmaceutical Co.

What is the business model of Taiko Pharmaceutical Co

No history available for Taiko Pharmaceutical Co.

What is the Taiko Pharmaceutical Co dividend?

Taiko Pharmaceutical Co pays a dividend of 0 JPY distributed over payouts per year.

How often does Taiko Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Taiko Pharmaceutical Co or the company does not pay out a dividend.

What is the Taiko Pharmaceutical Co ISIN?

The ISIN of Taiko Pharmaceutical Co is JP3442200006.

What is the Taiko Pharmaceutical Co ticker?

The ticker of Taiko Pharmaceutical Co is 4574.T.

How much dividend does Taiko Pharmaceutical Co pay?

Over the past 12 months, Taiko Pharmaceutical Co paid a dividend of 23.67 JPY . This corresponds to a dividend yield of about 5.24 %. For the coming 12 months, Taiko Pharmaceutical Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Taiko Pharmaceutical Co?

The current dividend yield of Taiko Pharmaceutical Co is 5.24 %.

When does Taiko Pharmaceutical Co pay dividends?

Taiko Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, January.

How secure is the dividend of Taiko Pharmaceutical Co?

Taiko Pharmaceutical Co paid dividends every year for the past 0 years.

What is the dividend of Taiko Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Taiko Pharmaceutical Co located?

Taiko Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taiko Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taiko Pharmaceutical Co from 3/31/2021 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 12/29/2020.

When did Taiko Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/31/2021.

What was the dividend of Taiko Pharmaceutical Co in the year 2023?

In the year 2023, Taiko Pharmaceutical Co distributed 0 JPY as dividends.

In which currency does Taiko Pharmaceutical Co pay out the dividend?

The dividends of Taiko Pharmaceutical Co are distributed in JPY.

All fundamentals about Taiko Pharmaceutical Co

Our stock analysis for Taiko Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taiko Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.